Related Experiment Video
Updated: Apr 18, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction
Ali Gholamzadeh1, Sara Amini, Amir H Mohammadpour
1*Department of Pharmaceutical Science, Faculty of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran; †Department of Cardiology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran; ‡Department of Pharmacodynamics and Toxicology, Faculty of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran; and §Cardiac Electrophysiology Research Center, Rajaie Cardiovascular Medical and Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Insights
Erythropoietin (EPO) administration significantly reduced arrhythmias in ST-elevation myocardial infarction (MI) patients post-percutaneous coronary intervention (PCI). This finding suggests EPO may be a novel therapeutic for preventing sudden cardiac death after MI.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Arrhythmia is a primary cause of sudden death following myocardial infarction (MI).
- Erythropoietin (EPO) has demonstrated potential in animal models to reduce post-MI arrhythmia incidence.
Purpose of the Study:
- To investigate the efficacy of high-dose erythropoietin (EPO) in preventing arrhythmias in patients with ST-elevation myocardial infarction (MI) after percutaneous coronary intervention (PCI).
Main Methods:
- 40 ST-elevation MI patients were randomized to receive either 33,000 IU EPO or placebo.
- Arrhythmias were monitored for 24 hours post-PCI using 12-lead ECG.
- Cardiac biomarkers (CK-MB), hematologic, and hemodynamic data were assessed within two weeks.
Main Results:
- The EPO group showed a significantly lower incidence of arrhythmias (20%) compared to the placebo group (35%, P=0.043).
- No significant differences were observed in the type of arrhythmias, CK-MB levels, or hematologic/hemodynamic parameters between the groups.
Conclusions:
- High-dose EPO administration, alongside primary PCI and antiplatelet therapy, effectively reduces arrhythmias in ST-elevation MI patients.
- Further well-designed clinical trials are necessary for definitive clinical interpretation and application of these findings.
Background:
Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI.
Methods:
We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI arrhythmia in 40 patients with ST-elevation MI who were randomly assigned in either EPO or placebo groups. Arrhythmias were blindly documented using full 12-lead configuration during 24 hours after percutaneous coronary intervention (PCI) by a cardiologist. Afterward, CK-MB, hematologic, and hemodynamic data were examined within 2 weeks after MI.
Results:
A comparison made between the 2 groups showed significant differences in the incidence of arrhythmias (20% in EPO group and 35% in placebo group, P = 0.043). However, no significant differences in type of arrhythmias were observed between the groups. There was no significant difference between levels of CK-MB in the 2 groups during 24 hours (P = 0.186). Hematologic and hemodynamic data showed no significant changes 2 weeks after PCI.
Conclusion:
High-dose administration of EPO in patients with ST-elevation MI who have been treated by primary PCI and standard antiplatelet therapy reduces the occurrence of arrhythmias. For clinical interpretation of the results, further well-designed trials are required.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:14Myocarditis III: Medical Management
01:30Heart Failure V: Medical Management
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:27Coronary Artery Disease V: Interprofessional Care
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias